which compared the 200mcg misprostol
vaginal insert (MVI) (n=678) with the 10-mg dinoprostone vaginal insert (DVI) (n=680) in terms of efficacy and safety in induction of labour in pregnant women with an unfavourable cervix.
The authors conclude that oxytocin may be preferable to providers and policymakers concerned about side effects, whereas misprostol
may be preferred because of ease of storage (unlike oxytocin, it does not need to be refrigerated) and delivery (the tablet can be administered by staff not trained or authorized to administer intravenous infusions).
Increasingly, first trimester miscarriage is treated medically, through use of misprostol
to cause contractions to evacuate the uterus, or through expectant management, that is, letting the miscarriage take its natural course.